25 July 16:50
The first twice-daily injectable HIV prevention drug based on lenacapavir has received CHMP recommendation for authorization, promising an effective and affordable solution.
Cristina Petrache
Health
Foto pexels.com
Lenacapavir is the first twice-daily injectable drug for the prevention of HIV infection, with 99.9% efficacy in clinical trials. Recommended by the CHMP, this treatment simplifies prevention by eliminating the need for daily tablets. In Romania, where the cost of HIV treatment is high, the new PrEP could reduce costs and improve access for vulnerable people. Approved at European level, this drug represents a significant opportunity to transform HIV prevention into public health policy.
Sources
Europa se apropie de aprobarea primului tratament PrEP injectabil cu administrare la 6 luni - o şansă uriaşă pentru prevenţia HIV în România
Europa se apropie de aprobarea primului tratament PrEP injectabil cu administrare la 6 luni - o șansă uriașă pentru prevenția HIV în România
Omenirea, mai aproape ca niciodată de a opri virusul HIV. Europa a autorizat tratamentul revoluționar
E.U. regulator approves injectable HIV drug that experts say could help stop transmission
EU regulator approves injectable HIV drug that experts say could help stop transmission
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
